JY
UNCY icon

Jeff Yass’s Unicycive Therapeutics UNCY Stock Holding History

Jeff Yass’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.57M Buy
334,800
+260,200
+349% +$1.92M ﹤0.01% 7049
2026
Q1 		$491K Buy
74,600
+48,300
+184% +$317K ﹤0.01% 9713
2025
Q4 		$152K Buy
+26,300
New +$140K ﹤0.01% 11157

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Jeff Yass's UNCY Position: Q2 2026 in Review

Jeff Yass reduced its Unicycive Therapeutics (UNCY) stake by 20% in Q2 2026, selling an estimated $289K and leaving 160,039 shares worth $751K. The position accounts for ﹤0.01% of the portfolio, ranked #8934.

Jeff Yass first reported a position in UNCY in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.31M in Q1 2026. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Jeff Yass held 160,039 shares of Unicycive Therapeutics worth $751K as of Q2 2026.
  • Jeff Yass sold 39,180 Unicycive Therapeutics shares in Q2 2026, an estimated $289K.
  • Unicycive Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #8934 holding.
  • Jeff Yass first reported a position in Unicycive Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Jeff Yass's Unicycive Therapeutics position peaked at $1.31M in Q1 2026.
  • 80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.